J&J subsidiary Janssen inked a collaboration deal to develop Protagonist Therapeutics’ PTG-200 for various gastrointestinal diseases.
U.S. drugmaker Pfizer Inc. reached an agreement with Sangamo Therapeutics Inc. for rights to its gene therapy programs to treat the rare blood-clotting disorder hemophilia A.
Amgen may need a bigger boat. The company is eying the use of shark-inspired antibodies called soloMERs to go after two undisclosed intracellular targets.
Immunomedics’ chief executive office and chief scientific officer will step down. Also, Seattle Genetics backed out of a $2 billion deal with the company.
Allergan plc said it would get exclusive access and the option to license up to five of Editas Medicine Inc.’s experimental gene-editing-based eye treatments under a research and development deal between the two companies.
Paris-based Sanofi Pasteur announced that it had inked a development agreement with MedImmune, the research-and-development art of AstraZeneca.
For the world’s drug makers 2016 was a year of two halves. Dealmaking and venture funding held up over the first two quarters, buoyed by the retreating bull market. However, as the US presidential election loomed ever closer, companies went into lockdown. Meanwhile, the medtech sector demonstrated that greater efforts are needed to foster innovation if it is to thrive. These findings and more were released as part of the Pharma & Biotech 2016 in Review and Medtech 2016 in Review reports by EP Vantage, the editorial arm of life science market intelligence firm Evaluate.
Drug developer Immunomedics Inc. entered into a development and licensing deal worth up to $2 billion for its experimental cancer drug with Seattle Genetics Inc.
A blow to Actelion’s Opsumit drug in a test is unlikely to have an impact on talks over a strategic deal with Johnson & Johnson, analysts said.